NYSE · Biotech stocks database
NVO (Novo Nordisk A/S) stock: $40.29, $178.40B market cap, $3.98B cash, $194.13B EV, $179.89B fully diluted market cap. Data from Fully Diluted's biotech stocks database.
The Company manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. Headquartered in Denmark, Novo Nordisk employs more than 69,500 employees in around 80 countries, and markets its products in approximately 170 countries.
Source: 20-F FY2025 via SEC EDGAR
| Cash | $3,984.0M |
|---|---|
| Debt | $19,715.2M |
| Net cash | -$15,731.1M |
| Enterprise value | $194,132.4M |
| Basic shares | 4,427.9M shares |
| Fully diluted shares | 4,465.0M shares |
| Fully diluted market cap | $179,894.9M |
| Cash per share | $0.90 |
Cash figures as of 2025-12-31. Database snapshot: 2026-11-07.
Cap table as of 2025-12-31.
Loading NVO daily closes…
NNC0519-0130 · Now - Nov 24, 2026 Now · Phase 2 · Chronic Kidney Disease
| Expected | Drug | Phase | Indication | Mgmt guide |
|---|---|---|---|---|
| Now - Nov 24, 2026 Now | NNC0519-0130 | Phase 2 | Chronic Kidney Disease | — |
| Now - Dec 5, 2026 Now | NNC0194-0499 | Phase 1 | Diabetes Mellitus, Type 1 | — |
| GUIDEDEst. Nov 15, 2026 Now quarter midpoint | CagriSema CagriSema FDA decision for weight management | Not disclosed | weight management | Q4 2026 |
| Nov 12 - Dec 24 in 5d | Ziltivekimab | Phase 3 | Heart Failure; Systemic Inflammation | — |
| Nov 12 - Dec 24 in 5d | Debio 1453P | Phase 1 | Healthy Participants | — |
| Jan 24 - Mar 7 in 11 wks | Liraglutide | Phase 1 | Obesity | — |
| Jan 25 - Mar 8 in 11 wks | NNC0662-0419 | Phase 2 | Overweight; Obesity | — |
| Feb 11 - Mar 25 in 14 wks | CDR132L (i.v.) | Phase 1 | Healthy Volunteers; Heart Failure | — |
| Feb 11 - Mar 25 in 14 wks | Semaglutide Pen Injector [Ozempic] | Phase 2 | Intestinal Mucositis; Inflammation; Chemotherapeutic Toxicity | — |
| Feb 25 - Apr 8 in 16 wks | UBT251 | Phase 2 | Overweight; Obesity | — |
| Feb 26 - Apr 9 in 16 wks | NNC0537-1482 | Phase 1 | Heart Failure | — |
| Mar 4 - Apr 15 in 17 wks | NNC6989-0001 | Phase 1 | Overweight; Obesity | — |
| Mar 8 - Apr 19 in 4 mo | Insulin icodec | Phase 3 | Diabetes Mellitus, Type 1 | — |
| Mar 9 - Apr 20 in 4 mo | Glucose-dependent Insulinotropic Polypeptide (GIP) | Phase 1 | Overweight; Obese | — |
| Mar 12 - Apr 23 in 4 mo | Ziltivekimab | Phase 3 | Cardiovascular Risk; Acute Myocardial Infarction (AMI) | — |
| Mar 14 - Apr 25 in 4 mo | NNC0113-5840 | Phase 1 | Obesity; Overweight | — |
| Mar 19 - Apr 30 in 4 mo | NNC0442-0344 A | Phase 1 | Haemophilia A | — |
| Apr 11 - May 23 in 5 mo | Amicidin-β topical solution - 15 mL | Phase 1 | Surgical Wound Infection; Traumatic Wound Infection | — |
| Apr 12 - May 24 in 5 mo | CagriSema (Cagrilintide B and Semaglutide I) | Phase 3 | Obesity | 1H 2027 Est. Apr 12, 2027 · PCD + 6 wks (Mar 29-Apr 26) |
| May 19 - Jun 30 in 6 mo | UBT251 | Phase 1 | Obesity; Overweight | — |
| May 20 - Jul 1 in 6 mo | NNC0662-0419 | Phase 1 | Overweight; Obesity | — |
| May 25 - Jul 6 in 7 mo | Cagrilintide | Phase 1 | Overweight; Obesity | — |
| Jun 7 - Jul 19 in 7 mo | LTB-NG6 | Phase 1 | Neisseria Gonorrhea | — |
| Jun 8 - Jul 20 in 7 mo | UBT251 | Phase 1 | Overweight; Obesity | — |
| Jun 22 - Aug 3 in 8 mo | Cagrilintide | Phase 3 | Obesity; Overweight | — |
| Jun 23 - Aug 4 in 8 mo | Cagrilintide | Phase 3 | Overweight; Obesity; Type 2 Diabetes | — |
| Jun 25 - Aug 6 in 8 mo | NNC4005-001 | Phase 1 | Fatty Liver Disease | — |
| Jun 27 - Aug 8 in 8 mo | CDR132L | Phase 2 | Heart Failure | — |
| Jun 29 - Aug 10 in 8 mo | Cagrilintide | Phase 3 | Overweight; Obesity | — |
| Jul 9 - Aug 20 in 8 mo | Cagrilintide D | Phase 1 | Obesity; Overweight | — |
| Jul 11 - Aug 22 in 8 mo | Coramitug | Phase 1 | Transthyretin Amyloid Cardiomyopathy | — |
| Jul 21 - Sep 1 in 9 mo | CagriSema | Phase 3 | Diabetes Mellitus, Type 2 | — |
| Aug 17 - Sep 28 in 9 mo | NNC0537-1482 | Phase 1 | Chronic Kidney Disease | — |
| Aug 23 - Oct 4 in 10 mo | NNC0662-0419 | Phase 2 | Obesity | — |
| Sep 12 - Oct 24 in 10 mo | NNC0705-0002 | Phase 1 | Healthy Volunteers; Cardiometabolic Diseases | — |
| Sep 14 - Oct 26 in 10 mo | NNC6022-0004 | Phase 1 | Obesity; Elevated High-sensitivity C-reactive Protein (hsCRP) | — |
| Oct 8 - Nov 19 in 11 mo | Etavopivat | Phase 3 | Sickle Cell Disease | — |
| Oct 13 - Nov 24 in 11 mo | Cagrilintide | Phase 3 | Cardiovascular Disease | — |
| Oct 15 - Nov 26 in 11 mo | NNC0662-0419 | Phase 2 | Diabetes Mellitus, Type 2 | — |
| Oct 27 - Dec 8 in 12 mo | INV-347 | Phase 1 | Obesity | — |
| Nov 4 - Dec 16 in 12 mo | NNC0721-8060 | Phase 1 | Overweight; Obesity | — |
| Nov 15 - Dec 27 in 12 mo | UBT251 | Phase 2 | Diabetes Mellitus, Type 2 | — |
| Nov 22, 2027 - Jan 3, 2028 in 13 mo | NNC0638-0355 | Phase 1 | Obesity; Overweight | — |
| Nov 22, 2027 - Jan 3, 2028 in 13 mo | NNC0581-0001 | Phase 1 | Healthy Volunteers; Hepatic Steatosis | — |
| Nov 23, 2027 - Jan 4, 2028 in 13 mo | CagriSema (Cagrilintide B | Phase 1 | Obesity | — |
| Dec 19, 2027 - Jan 30, 2028 in 14 mo | Semaglutide | Phase 3 | Diabetes Mellitus, Type 2 | — |
| Dec 23, 2027 - Feb 3, 2028 in 14 mo | NNC0487-0111 | Phase 1 | Diabetes Mellitus | — |
| Dec 28, 2027 - Feb 8, 2028 in 14 mo | CDR132L | Phase 2 | Heart Failure | — |
| Dec 31, 2027 - Feb 11, 2028 in 14 mo | Cagrilintide | Phase 1 | Obesity; Overweight | — |
| Jan 12 - Feb 23 in 14 mo | NNC0487-0111 | Phase 1 | Overweight; Obesity | — |
| Feb 12 - Mar 25 in 15 mo | Recombinant Activated Factor VII (rFVIIa) | Phase 3 | Intracerebral Hemorrhage | — |
| Mar 1 - Apr 12 in 16 mo | NNC0487-0111 | Phase 1 | Obesity | — |
| Mar 31 - May 12 in 17 mo | NNC0497-0040 | Phase 1 | Type 1 Diabetes (T1D); Overweight; Obesity | — |
| Apr 4 - May 16 in 17 mo | Semaglutide | Phase 3 | Overweight; Obesity | — |
| Apr 5 - May 17 in 17 mo | Cagrisema | Phase 3 | Obesity; Type 2 Diabetes | 1H 2027 Est. Jun 30, 2027 · PCD + 6 wks (Jun 30-Jun 30) |
| Apr 5 - May 17 in 17 mo | Etavopivat | Phase 2 | Sickle Cell Disease | — |
| Apr 11 - May 23 in 17 mo | NNC6019-0001 | Phase 2 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | — |
| Apr 26 - Jun 7 in 18 mo | NNC9733-0001 | Phase 1 | Healthy Volunteer; Type 2 Diabetes | — |
| Jun 9 - Jul 21 in 19 mo | Cagrilintide | Phase 1 | Obesity | — |
| Jun 14 - Jul 26 in 20 mo | Cagrilintide | Phase 1 | Obesity | — |
| Jul 18 - Aug 29 in 21 mo | NNC0487-0111 | Phase 3 | Obesity | — |
| Jul 24 - Sep 4 in 21 mo | Zenagamtide injection | Phase 1 | Overweight; Obesity | — |
| Aug 6 - Sep 17 in 21 mo | NNC1679-0001 | Phase 1 | Healthy Volunteers; Diabetes Mellitus, Type 2 | — |
| Aug 7 - Sep 18 in 21 mo | NNC0487-0111 | Phase 3 | Obesity; Overweight; Obstructive Sleep Apnoea | — |
| Aug 8 - Sep 19 in 21 mo | zenagamtide | Phase 3 | Overweight; Obesity | — |
| Aug 11 - Sep 22 in 21 mo | Mim8 | Phase 3 | Haemophilia A; Haemophilia A With Inhibitors | — |
| Aug 23 - Oct 4 in 22 mo | NNC0487-0111 | Phase 3 | Obesity; Overweight; Obstructive Sleep Apnoea | — |
| Sep 11 - Oct 23 in 22 mo | Zenagamtide | Phase 3 | Type 2 Diabetes; Cardiovascular Risk | — |
| Sep 18 - Oct 30 in 23 mo | NNC0487-0111 | Phase 3 | Diabetes Mellitus; Overweight; Obesity | — |
| Sep 25 - Nov 6 in 23 mo | NNC0487-0111 | Phase 3 | Obesity; Knee Osteoarthritis (OA) | — |
| Sep 25 - Nov 6 in 23 mo | NNC0487-0111 | Phase 3 | Obesity; Overweight; Osteoarthritis, Knee | — |
| Oct 9 - Nov 20 in 23 mo | Cagrilintide | Phase 3 | Obesity | 1H 2027 Est. Jun 30, 2027 · PCD + 6 wks (Jun 30-Jun 30) |
| Oct 13 - Nov 24 in 24 mo | Ziltivekimab | Phase 3 | Coronary Artery Disease; Acute Myocardial Infarction (AMI); Coronary Atherosclerosis of Native Coronary Artery | — |
| Oct 30 - Dec 11 in 24 mo | NNC0487-0111 | Phase 1 | Overweight; Obesity | — |
| Nov 21, 2028 - Jan 2, 2029 in 25 mo | Zenagamtide | Phase 3 | Overweight; Obesity | — |
| Dec 26, 2028 - Feb 6, 2029 in 26 mo | Ziltivekimab | Phase 3 | Myocardial Infarction | — |
| Jan 23 - Mar 6 in 27 mo | NNC0487-0111 | Phase 3 | Obesity; Overweight; Diabetes Mellitus, Type 2 | — |
| Feb 12 - Mar 26 in 28 mo | Recombinant Factor VIIa | Phase 3 | Intracerebral Hemorrhage | — |
| Feb 22 - Apr 5 in 28 mo | Zenagamtide | Phase 3 | Obesity; Overweight | — |
| Jun 6 - Jul 18 in 31 mo | Semaglutide | Phase 3 | Non-alcoholic Steatohepatitis | — |
| Aug 7 - Sep 18 in 33 mo | NNC0487-0111 | Phase 3 | Obesity | — |
| Aug 10 - Sep 21 in 34 mo | NNC6019-0001 | Phase 3 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | — |
| Sep 3 - Oct 15 in 34 mo | NNC0487-0111 | Phase 3 | Obesity; Heart Failure | — |
| Oct 19 - Nov 30 in 36 mo | CagriSema (Cagrilintide B and Semaglutide I) | Phase 3 | Diabetes Mellitus, Type 2 | — |
| May 1 - Jun 12 in 42 mo | Cagrilintide | Phase 3 | Overweight; Obesity | 1H 2027 Est. Jun 30, 2027 · PCD + 6 wks (Jun 30-Jun 30) |
| May 13 - Jun 24 in 43 mo | DCR-PHXC | Phase 3 | Primary Hyperoxaluria Type 1 (PH1); Primary Hyperoxaluria Type 2 (PH2); Kidney Diseases | — |
| Feb 10 - Mar 24 in 52 mo | Etavopivat A | Phase 3 | Sickle Cell Disease; Thalassemia | — |
| Feb 10 - Mar 23 in 64 mo | DCR-PHXC | Phase 2 | Primary Hyperoxaluria Type 1; End Stage Renal Disease | — |
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Per-asset detail extracted from the 20-F filed 2026-02-04. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
| Trial | Phase | Status | Role | Sponsor | BP | Condition(s) | Mgmt guide |
|---|---|---|---|---|---|---|---|
| NCT06200207 | Phase 3 | Active, not recruiting | Sponsor | NVO | — | Heart Failure; Systemic Inflammation | — |
| NCT07076199 | Phase 3 | Active, not recruiting | Sponsor | NVO | — | Diabetes Mellitus, Type 1 | — |
| NCT06118281 | Phase 3 | Active, not recruiting | Sponsor | NVO | — | Cardiovascular Risk; Acute Myocardial Infarction (AMI) | — |
| NCT07011667 | Phase 3 | Active, not recruiting | Sponsor | NVO | — | Obesity | 1H 2027 Est. Apr 12, 2027 · PCD + 6 wks (Mar 29-Apr 26) |
| NCT07220642 | Phase 3 | Active, not recruiting | Sponsor | NVO | — | Obesity; Overweight | — |
| NCT07220759 | Phase 3 | Active, not recruiting | Sponsor | NVO | — | Overweight; Obesity; Type 2 Diabetes | — |
| NCT07745504 | Phase 3 | Recruiting | Sponsor | NVO | — | Overweight; Obesity | — |
| NCT07817251 | Phase 3 | Not yet recruiting | Sponsor | NVO | — | Diabetes Mellitus, Type 2 | — |
| NCT06612268 | Phase 3 | Recruiting | Sponsor | NVO | — | Sickle Cell Disease | — |
| NCT05669755 | Phase 3 | Active, not recruiting | Sponsor | NVO | — | Cardiovascular Disease | — |
| NCT03811561 | Phase 3 | Active, not recruiting | Sponsor | NVO | — | Diabetes Mellitus, Type 2 | — |
| NCT07770841 | Phase 3 | Recruiting | Sponsor | NVO | — | Overweight; Obesity | — |
Sponsor-matched active trials from ClinicalTrials.gov (132 as sponsor, 63 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
View all 195 active trials for Novo Nordisk A/S on ClinicalTrials.gov
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
| Fund | Shares | Q/Q change | % of portfolio | Filing |
|---|---|---|---|---|
| Sphera Biotech | 120,677 | no change | 0.83% | 2026-08-14 |
| ADAR1 Capital Management | 27,000 | -6,000 | 0.06% | 2026-08-14 |
Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.